W
Walter M. Stadler
Researcher at University of Chicago
Publications - 513
Citations - 37554
Walter M. Stadler is an academic researcher from University of Chicago. The author has contributed to research in topics: Cancer & Prostate cancer. The author has an hindex of 88, co-authored 494 publications receiving 34323 citations. Previous affiliations of Walter M. Stadler include Cleveland Clinic & Northwestern University.
Papers
More filters
Journal ArticleDOI
Phase II study of the efficacy and safety of oral GD0039 in patients with locally advanced or metastatic renal cell carcinoma.
Philip E. Shaheen,Walter M. Stadler,Paul Elson,Jennifer J. Knox,Eric Winquist,Ronald M. Bukowski +5 more
TL;DR: No evidence of anti-tumor activity of GD0039 was seen in this study.
Journal ArticleDOI
Multi-institutional quality-of-care initiative for nonmetastatic, muscle-invasive, transitional cell carcinoma of the bladder: Phase I.
Andrew Feifer,Jennifer M. Taylor,Marwan Shouery,Gary D. Steinberg,Walter M. Stadler,Mark P. Schoenberg,Alexander Zlotta,Seth P. Lerner,Dean F. Bajorin,Bernard H. Bochner +9 more
TL;DR: Despite level 1 evidence that cisplatin based neoadjuvant chemotherapy is associated with a survival advantage, only a small percentage of eligible patients undergoing radical cystectomy for muscle invasive, resectable disease receive combined treatment.
Journal ArticleDOI
Low‐grade prostate cancer diverges early from high grade and metastatic disease
David J. VanderWeele,Christopher D. Brown,Jerome B. Taxy,Marc Gillard,David M. Hatcher,Westin Tom,Walter M. Stadler,Kevin P. White +7 more
TL;DR: Analysis of laser microdissection followed by exome sequencing of low‐ and high‐grade prostate cancer foci from four subjects, and metastatic disease from two of those subjects, to evaluate the molecular relationship of coincidentcancer foci provides insights into the development of high‐ grade and metastatics prostate cancer.
Journal ArticleDOI
Dasatinib in previously treated metastatic colorectal cancer: a phase II trial of the University of Chicago Phase II Consortium
Manish R. Sharma,Kristen Wroblewski,Blase N. Polite,James A. Knost,James A. Wallace,Sanjiv Modi,Bethany G. Sleckman,David A. Taber,Everett E. Vokes,Walter M. Stadler,Hedy L. Kindler +10 more
TL;DR: Dasatinib is inactive as a single agent in previously treated metastatic CRC patients, and has antitumor activity in CRC xenograft models.
Journal ArticleDOI
Quantitative characterization of androgen receptor protein expression and cellular localization in circulating tumor cells from patients with metastatic castration-resistant prostate cancer
Edwin E. Reyes,David J. VanderWeele,Masis Isikbay,Ryan Duggan,Alexa Campanile,Walter M. Stadler,Donald J. Vander Griend,Russell Z. Szmulewitz +7 more
TL;DR: Evaluated CTC interrogation with respect to the AR found increased AR expression and nuclear localization are associated with elevated co-expression of Ki-67, consistent with the continued role for AR in castration-resistant disease.